The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Baymeeva N.V.

Mental Health Research Center, Moscow

Miroshnichenko I.I.

Mental Health Research Center

Platova A.I.

Mental Health Reseroch center

Tikhonov D.V.

Mental Health Research Center

Kaleda V.G.

Mental Health Research Centre

Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia

Authors:

Baymeeva N.V., Miroshnichenko I.I., Platova A.I., Tikhonov D.V., Kaleda V.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1): 98‑103

DOI: 10.17116/jnevro202212201198

Read: 1402 times

Download PDF (RU)
Contact the author
Table of contents

THERAPEUTIC DRUG MONITORING OF ARIPIPRAZOLE AS PART OF THE INDIVIDUALIZATION OF THE PHARMACOTHERAPY OF SCHIZOPHRENIA
THERAPEUTIC DRUG MONITORING OF ARIPIPRAZOLE AS PART OF THE INDIVIDUALIZATION OF THE PHARMACOTHERAPY OF SCHIZOPHRENIA

To cite this article:

Baymeeva NV, Miroshnichenko II, Platova AI, Tikhonov DV, Kaleda VG. Therapeutic drug monitoring of aripiprazole as part of the individualization of the pharmacotherapy of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1):98‑103. (In Russ.)
https://doi.org/10.17116/jnevro202212201198

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Auto­mated method for measuring L-asparaginase acti­vity. Labo­ratory Service. 2025;(1):32-37
Abstract:

OBJECTIVE

To personalize pharmacotherapy with aripiprazole in patients with schizophrenia via therapeutic drug monitoring (TDM).

MATERIAL AND METHODS

TDM of aripiprazole (ARI) and its active metabolite dehydroaripiprazole (DHA) was performed for patients diagnosed with schizophrenia (ICD-10 F20.00; F20.01; F20.02). Thirty-six parameters were assessed. To carry out TDM, the method of high-performance liquid chromatography with mass spectrometry was chosen employing a validated method.

RESULTS

TLM was performed in a group of young patients: 26.5±10.1 years old, average weight 77.2±16.2 kg, average PANSS score 81.4±21.4, UKU score 14.5±3.9. An average ARI concentration was 18.4±7.9 mg, serum ARI concentration 417.9±362.4 ng/ml, serum DHA concentration 117.5±116.1 ng/ml and the total concentration 535.4±478.5 ng/ml. Equations of correlation dependences of concentration on dose are obtained for ARI and DHA.

CONCLUSION

The results show the significant metabolism of ARI. A combined determination of the main substance and its active metabolite DHA in the patient’s blood serum is advisable for correct assessment of the TLM result in patients with mental diseases.

Keywords:

aripiprazole
dehydroaripiprazole
therapeutic drug monitoring
high performance liquid chromatography with mass spectrometry

Authors:

Baymeeva N.V.

Mental Health Research Center, Moscow

Miroshnichenko I.I.

Mental Health Research Center

Platova A.I.

Mental Health Reseroch center

Tikhonov D.V.

Mental Health Research Center

Kaleda V.G.

Mental Health Research Centre

Received:

19.11.2020

Accepted:

25.03.2021

Close metadata

References:

  1. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2-receptors. J Pharmacol Exp Ther. 2002;302:381-389.  https://doi.org/10.1124/jpet.102.033175
  2. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. Eur J Pharmacol. 2002;441:137-140.  https://doi.org/10.1016/s0014-2999(02)01532-7
  3. Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna C, Di Pace, Altamura AC. Clinical pharmacology of atypical antipsychotics: an update. EXCLI Journal. 2014;13:1163-1191. https://doi.org/10.1007/s40262-019-00797-7
  4. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. The Journal of Clinical Pharmacology. 2004;2:179-187.  https://doi.org/10.1177/0091270003261901
  5. Yokoi F, Grunder G, Biziere K, Stephane M, Dogman AS, Dannals RF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology. 2002;27:248-259.  https://doi.org/10.1016/s0893-133x(02)00304-4
  6. Weber J, Lyseng-Williamson KA, Scott LJ. Aripiprazole in major depressive disorder. CNS Drugs. 2008;22:807-813.  https://doi.org/10.2165/00023210-200822100-00002
  7. Patel DP, Sharma P, Sanyal M, Shrivastav PS. SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support abioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;925:20-25.  https://doi.org/10.1016/j.jchromb.2013.02.022
  8. Winans E. Aripiprazole. Am J Health Syst Pharm. 2003;60:2437-2445. https://doi.org/10.1093/ajhp/60.23.2437
  9. Waade RB, Christensen H, Rudberg I, Refsum H, Hermann M. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Therapeutic Drug Monitoring. 2009;2:233-238.  https://doi.org/10.1097/ftd.0b013e3181956726
  10. Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Hiemke C, Remschmidt H. Theisen Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Therapeutic Drug Monitoring. 2008;30:462-466.  https://doi.org/10.1097/ftd.0b013e318178e18d
  11. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93.  https://doi.org/10.1093/ajhp/60.23.2437
  12. https://www.drugbank.ca/
  13. Miroshnichenko II, Baymeeva NV. Simultaneous determination of antipsychotic drugs and their active metabolites by LC—MS-MS and its application to therapeutic drug monitoring. Journal of Chromatographic Science. 2018;6:510-517.  https://doi.org/10.1093/chromsci/bmy024
  14. Baymeeva NV, Platova AI, Kaleda VG, Miroshnichenko II. Therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3):24-28. (In Russ.). https://doi.org/10.30906/0023-1134-2016-50-5-50-56
  15. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. The Journal of Clinical Pharmacology. 2004;2:179-187.  https://doi.org/10.1177/0091270003261901
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.